• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

AI tool matches cancer patients with relevant clinical trials

Share:

March 12, 2019

A 14-week health technology “sprint” sponsored by the U.S. Census Bureau and coordinated by the HHS has produced an AI tool that developers claim could revolutionize the way researchers match cancer patients with clinical trials.

The tool, a novel knowledge graph created by a team at the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute, was developed as part of The Opportunity Project Health Sprint, according to a release. Oak Ridge’s team was just 1 of 10 to develop a digital tool to address challenges relevant to medical conditions like cancer or Lyme disease.

Spearheaded by project lead Ioana Danciu, the scientists applied unsupervised machine learning and large-scale graph analytic methodologies to open datasets provided by governmental agencies like the National Cancer Institute and Department of Veterans Affairs. Danciu and her colleagues added clinical trial data to an exoscale knowledge graph that continuously collects and connects data across sources like EHRs and medical ontologies.

“One of the major obstacles facing cancer trial eligibility is the unstructured nature of the data,” Danciu said in the release. “Artificial intelligence and natural language processing tools refine and advance the process of matching cancer patients to promising clinical trials.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Using AI approaches similar to what Netflix uses to tailor its movie suggestions, the team was able to present information in a much clearer, more meaningful way.

According to the release, the TOP project built upon existing AI research at the Oak Ridge lab, which so far has been used to extract information with signals from low signal-to-noise ratios, developed algorithms capable of accelerating modeling and simulation with little training data and designed novel biomimetic neuromorphic devices capable of detecting epileptic seizures.

“This was an exploratory project,” Danciu said. “Ultimately, we are interested in unleashing the power of the unique computing resources and data science expertise available at ORNL to find end-to-end solutions to big problems with broad societal impact, and clinical trial patient matching certainly fits that description.”

Date: March 13, 2019

Source: AI in Healthcare

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Teledyne Completes Acquisition of Scientific Imaging Businesses of Roper TechnologiesTeledyne Completes Acquisition of Scientific Imaging Businesses of Roper Technologies
  • Apollo Medical Holdings Announces Acquisition Of Accountable Health Care IPAApollo Medical Holdings Announces Acquisition Of Accountable Health Care IPA
  • Adare Pharmaceuticals, Inc. Acquires Orbis BiosciencesAdare Pharmaceuticals, Inc. Acquires Orbis Biosciences
  • ARTIS Ventures Closes $200M TechBio Fund to Support Next Era of Health & Medicine InnovationARTIS Ventures Closes $200M TechBio Fund to Support Next Era of Health & Medicine Innovation
  • Boehringer Ingelheim Signs Option to Acquire Trutino BiosciencesBoehringer Ingelheim Signs Option to Acquire Trutino Biosciences
  • Why B2C2B Will be the Future Go-to-Market Strategy for Virtual CareWhy B2C2B Will be the Future Go-to-Market Strategy for Virtual Care
  • Flow Depression Headset to Tackle UK’s ‘Lockdown Loneliness’Flow Depression Headset to Tackle UK’s ‘Lockdown Loneliness’
  • WNDM Medical acquires remaining 50% stake in CelleratWNDM Medical acquires remaining 50% stake in Cellerat

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications